Evidence map›Paper›PMID 32741046›Full record

ArticleGenes, brain, and behavior2020

Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in L-Dopa-induced dyskinesia in parkinsonian rats.

Shetty Ravi Dyavar, Lisa F Potts, Goichi Beck, Bhagya Laxmi Dyavar Shetty, Benton Lawson, Anthony T Podany, Courtney V Fletcher, Rama Rao Amara, Stella M Papa

Open access · greenAbstract read
In one paragraph

Article in Genes, brain, and behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Differential Activation States of Direct Pathway Striatal Output Neurons during l-DOPA-Induced Dyskinesia Development.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shetty Ravi DyavarDepartment of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-2141-7214
Lisa F PottsYerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Goichi BeckYerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Bhagya Laxmi Dyavar ShettyYerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Benton LawsonDepartment of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Anthony T PodanyCenter for Drug Discovery, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Courtney V FletcherCenter for Drug Discovery, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Rama Rao AmaraDepartment of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Stella M PapaYerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Oregon National Primate Research Center · USEmory University · USNebraska Medical Center · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Therapeutics Core (Page 286)P30MH062261 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BUCH, SHILPA J., FOX, HOWARD S · 2000 to 2021
$37.7M
Regulation of Motor Function in Parkinson's DiseaseR01NS045962 · NINDS · EMORY UNIVERSITY · PI PAPA, STELLA M, TRAYNELIS, STEPHEN F · 2004 to 2022
$5.2M
Manipulating Gene Expression in the Dyskinesias of Parkinson's DiseaseR01NS073994 · NINDS · EMORY UNIVERSITY · PI MOURADIAN, M. MARAL, PAPA, STELLA M · 2011 to 2016
$2.4M
Clinical Pharmacology of Efavirenz Combined with High Dose RifapentineK23AI134307 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PODANY, ANTHONY T · 2018 to 2022
$819k
Regulation of Motor Function in Parkinson's DiseaseR56NS045962 · NINDS · EMORY UNIVERSITY · PI PAPA, STELLA M, TRAYNELIS, STEPHEN F · 2018 to 2018
$603k
A novel gene therapy for motor symptoms of Parkinson's diseaseR21NS110416 · NINDS · EMORY UNIVERSITY · PI PAPA, STELLA M · 2019 to 2019
$483k
NIAID NIH HHS K23 AI134307NIH HHS P51 OD011132NIMH NIH HHS P30 MH062261NINDS NIH HHS R01 NS045962NINDS NIH HHS R01 NS073994NINDS NIH HHS R21 NS110416NINDS NIH HHS R56 NS045962
6 · The paper itself

Abstract

Dyskinesia induced by long-term L-Dopa (LID) therapy in Parkinson disease is associated with altered striatal function whose molecular bases remain unclear. Here, a transcriptomic approach was applied for comprehensive analysis of distinctively regulated genes in striatal tissue, their specific pathways, and functional- and disease-associated networks in a rodent model of LID. This approach has identified transforming growth factor beta type 1 (TGFβ1) as a highly upregulated gene in dyskinetic animals. TGFβ1 pathway is a top aberrantly regulated pathway in the striatum following LID development based on differentially expressed genes (> 1.5 fold change and P < 0.05). The induction of TGFβ1 pathway specific genes, TGFβ1, INHBA, AMHR2 and PMEPA1 was also associated with regulation of NPTX2, PDP1, SCG2, SYNPR, TAC1, TH, TNNT1 genes. Transcriptional network and upstream regulator analyses have identified AKT-centered functional and ERK-centered disease networks revealing the association of TGFβ1, IL-1β and TNFα with LID development. Therefore, results support that TGFβ1 pathway is a major contributor to the pathogenic mechanisms of LID.

Indexed as

Signal TransductionTranscriptomeAnimalsAntiparkinson AgentsBrainDyskinesia, Drug-InducedGene Regulatory NetworksInhibin-beta SubunitsLevodopaMaleRatsRats, Sprague-DawleyReceptors, NeurotransmitterTachykininsTissue Inhibitor of Metalloproteinase-1Transforming Growth Factor beta1Antiparkinson Agentsinhibin beta A subunitInhibin-beta SubunitsLevodopaneuromedin U receptorReceptors, NeurotransmitterTachykininsTgfb1 protein, ratTIMP1 protein, ratTissue Inhibitor of Metalloproteinase-1Transforming Growth Factor beta1IL-1βinflammationINHBaL-Dopa-induced dyskinesiaNMUParkinson diseaseTAC1TGFβ1TNFα

Identifiers

PMID32741046
PMCPMC8006569
OpenAlexW3046687520

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.